書籍詳細

おわりに

P.144 掲載の参考文献

• 1) US Preventive Services Task Force:Guide to Clinical Preventive Services-An Assessment of the Effectiveness of 169 Interventions. Williams & Wilkins, 1989.

• 2) Easterbrook PJ:Directory of registries of clinical trials. Stat. Med. 11:345-423, 1992.
  pubmed

• 3) Dickersin K, Garcia-Lopez F:Regulatory process effects clinical trial registration in Spain. Controlled. Clin. Trials 13:507-512, 1992.
  pubmed

• 4) Bull JP:The historical development of clinical therapeutic trials. J. Chron. Dis. 10:218-248, 1959.
  pubmed

• 5) Lilienfeld AM:Ceteris paribus:The evaluation of the clinical trial. Bull. Hist. Med. 56:1-18, 1982.

• 6) Pocock SJ:Clinical Trials-A Practical Approach. John Wiley & Sons Ltd, Chichester, 1983.

• 7) Meinert CL:Clinical Trials-Design, Conduct, and Analysis. Oxford University Press, New York, 1986.

• 8) Medical Research Council:Clinical trials of new remedies. Lancet ii:304, 1931.

• 9) Abraham EP, Chain E, Fletcher CM, Gardner AD, Heatley NG, Jennings MA, Florey HW:Further observations on penicillin. Lancet ii:177-188, 1941.

• 10) Medical Research Council:Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:769-782, 1948.

• 11) Medical Research Council:Clinical trials of antihistamic drugs in the prevention and treatment of the common cold. Br. Med. J. 2:423-429, 1950.

• 12) Hill Sir AB:Statistical Methods in Clinical and Preventive Medicine. Oxford University Press, New York, 1962.

• 13) Schwartz D, Flamant R, Lellouch J:Clinical Trials. Healy MJR, Academic Press, London, 1980.

• 14) Shapiro SH, Louis TA:Clinical Trials. Issues and Approaches. Marcel Dekker, New York, 1983.

• 15) Friedman LM Furberg CD, DeMets DL:Fundamentals of Clinical Trials. 2nd ed. Littleton Mass, PSG Publishing, 1985.

• 16) Rotmensz N, Vantongelen K, Renard J eds:Data Management and Clinical Trials, EORTC Study Group on Data Management. Elsevier Science Publishers, New York, 1989.

• 17) Spilker B:Guide to Clinical Trials. Raven Press, New York, 1991.

• 18) Frei E, Holland JF, Schneiderman MA:A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13:1126-1148, 1958.
  pubmed

• 19) 唄 孝一:医薬品の臨床試験と倫理. 法律時報 59 (12) :37-45, 1987.

• 20) 厚生省薬務局審査第一課監修:GCPハンドブック. 薬業時報社, 1990.

• 21) 厚生省薬務局新医薬品課:臨床試験の統計解析に関するガイドライン. 平成4年3月4日薬新薬第20号新医薬品課長通知, 1992.

• 22) 厚生省薬務局新医薬品課:新医薬品の臨床評価に関する一般指針について. 平成4年6月29日薬新薬第43号新医薬品課長通知, 1992.

• 23) Hawkins BS:Controlled Clinical trials in the 1980s:A bibliography. Controlled. Clin. Trials 12:5-272, 1991.

• 24) 日本癌治療学会:日本癌治療学会・生存率算出規約 (案). 日癌治19:137-162, 1984.

• 25) 日本癌治療学会:固形がん化学療法効果判定基準. 日癌治 21:929-942, 1986.

• 26) 日本癌治療学会:抗がん剤の臨床評価に関する指針. 日癌治 21:955-968, 1986.

• 27) 抗悪性腫瘍薬の臨床評価ガイドライン作成に関する研究班:抗悪性腫瘍薬の臨床評価方法に関するガイドライン(案) , 1989.

• 28) 下山正徳, 富永祐民, 西條長宏, 大田満夫, 飯塚紀文, 中島聰總, 栗原 稔, 安達 勇, 土屋了介, 吉田茂昭, 飛内賢正, 恒松隆一郎, 渡辺 昌, 阿部 薫, 岡崎伸生, 中里博昭, 塚本哲也, 末舛恵一:厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班における臨床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析とその評価について (1990年改訂版). 癌の臨床 36:2503-2525, 1990.
  Medical*Online

• 29) 井口 潔:我が国の臨床試験の問題点と展望. 日本医事新報 3595:95-97, 1993.

• 30) 坂本純一, 加藤知行, 平井 孝, 中里博昭:International Computer Networkを介したEORTCのCentral Randomization Systemへの登録. 癌生時研誌 9:57-61, 1989.

• 31) Green SB, Byar DP:Using observational data from registries to compare treatments:the fallacy of omnimetrics. Stat. Med. 3:361-370, 1984.
  pubmed

• 32) Grace ND, Muench H, Chalmers TC:The present status of portal hypertension in cirrhosis. Gastroenterology 50:684-691, 1966.
  pubmed

• 33) Moertel CG:Atrial of Laetrile now. N. Engl. J. Med. 298:218-219, 1978.

• 34) Ellison NM, Byar D, Newell GR:Special report on Laetrile:The NCI Laetrile review, Results of the National Cancer Institute's Retrospective Laetrile Analysis. N. Engl. J. Med. 299:549-552, 1978.
  pubmed

• 35) Moertel CG, Flemming TR, Rubin J, Kvols L, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP:A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl. J. Med. 306:201-206, 1982.

• 36) Chalmers TC, Schroeder B:Controls in 'Journal' articles. N. Engl. J. Med. 287:75-78, 1979.

• 37) Chalmers TC, Block JB, Lee S:Controlled studies in clinical cancer research. N. Engl. J. Med. 287:75-78, 1972.
  pubmed

• 38) Gehan EA, Freireich EJ:Non-randomized controls in cancer clinical trials. N. Engl. J. Med. 290:198-203, 1974.
  pubmed

• 39) Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH:Randomized clinical trials:Perspectives on some recent ideas. Ar. Engl. J. Med. 295:74-80, 1976.

• 40) Cranberg L:Do retrospective controls rnake clinical trials 'inherently fallacious ?' Br. Med. J. ii:1265-1266, 1979.

• 41) Doll R, Peto R:Randomized controlled trials and retrospective controls. Br. Med. J. i:44, 1980.
  pubmed

• 42) Gelber RD, Goldhirsh A:Can a clinical trial be the treatment of choice for patients with cancer?JNCI 80:886-887, 1988.

• 43) Wittes RE, Friedman MA:Accrual to clinical trials. JNCI 80:884-885, 1988.
  pubmed

• 44) Royall RM:Ethics and statistics in randomized clinical trials. Stat. Sci. 6:52-62, 1991.
  pubmed

• 45) Passamani E:Clinical trials-are they ethical? N. Engl. J. Med. 324:1589-1592, 1991.
  pubmed

• 46) Coronary Drug Project Research Group:The Coronary Drug Project:Findings leading to modifications of its protocol with respect to dextrothyroxine. JAMA 220:996-1008, 1972.

• 47) Coronary Drug Project Research Group:Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975.

• 48) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators:Preliminary report:effect of encainide and flecainide on mortality in a randomized:trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321:406-412, 1989.

• 49) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension:Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 231:1028-1034, 1967.

• 50) Schwartz D, Lellouch J:Explanatory and pragmatic attitudes in therapeutical trials. J. Chron. Dis. 20:637-648, 1967.
  pubmed

• 51) Piantadosi S, Saijo N, Tamura T:Basic design considerations for clinical trials in oncology. Jpn J. Cancer. Res. 83:547-558, 1992.
  pubmed

• 52) Simes RJ:Application of statistical decision theory to treatment choices:Implications for the design and analysis of clinical trials. Stat. Med. 5:411-420, 1986.
  pubmed

• 53) Hilden J:Reporting clinical trials from the viewpoint of a patient's choice of treatment. Stat. Med. 6:745-752, 1987.

• 54) Freedman LS, Spiegelhalter DJ:Application of Bayesian statistics to decision making during a clinical trial. Stat. Med. 11:23-35, 1992.
  pubmed

• 55) Weinstein MC, Fineberg HV, Elstein AS, Frazier H, Neuhauser D, Neutra RR, McNeil BJ:Clinical Decision Analysis. WB Saunders Company, Philadelphia, 1980.

• 56) Sox HC, Blatt MA, Higgins MC, Marton K:Medical Decision Making. Butterworth Heinemann, Boston, 1988.

• 57) 福井次矢:臨床医の決断と心理Clinical Decision Making. 医学書院, 1988.

• 58) 久繁哲徳編:臨床判断学. 篠原出版, 1989.

• 59) 久道 茂:医療判断学入門. 南江堂, 1990.

• 60) Zelen M:Randomized consent designs for clinical trials:An update. Stat. Med. 9:645-656, 1990.
  pubmed

• 61) US Government Food and Drug Administration Code of Fedearal Regulations:DHEW publication. US Governmental Printing Office, Washington DC, pp.191-193, 1982.

• 62) Zelen M:A new design for randomized clinical trials. N. Engl. J. Med. 300:1242-1245, 1979.
  pubmed

• 63) Gardner MJ, Bond J:An exploratory study of statistical assessment of papers published in the British Medical Journal. JAMA 263:1355-1357, 1990.
  pubmed

• 64) 浜島信之:無作為比較対照試験におけるZelenの方法再考. 癌と化学療法 19:1953-1957, 1992.
  Medical*Online

• 65) Ellenberg SS:Randomization designs in comparative clinical trials. N. Engl. J. Med. 310:1404-1408, 1984.
  pubmed

• 66) 浜島信之:癌患者を対象とした市販後薬剤の無作為比較化対照試験とInformed Consent. 日癌治 27:1701-1706, 1992.

• 67) Diabetic Retinopathy Study Research Group:Preliminary report on effect of photocoagulation therapy. Am. J. Ophthalmol. 81:383-396, 1976.

• 68) Hills M, Armitage P:The two-period crossover clinical trial. Br. J. Clin. Pharmacol 1. 8:7-20, 1979.
  pubmed

• 69) Armitage P, Hills M:The two-period crossover trial. Statistician 28:171-183, 1982.

• 70) 最高裁判所事務総局:医療過誤関係民事訴訟事件執務資料. 法曹会, 1989.

• 71) 浜島信之:米国の病院におけるリスクマネージメント. 日本医事新報 3504:95-97, 1991.

• 72) 浜島信之:リスクマネージメントと米国における法的規制. 日本病院会雑誌 39:117-121, 1992.

• 73) 穴田秀男:最新医事法学. 金原出版, 1987.

• 74) 田中 実, 藤井輝久:医療の法律紛争. 有斐閣, pp.4-7, 1986.

• 75) 最高裁三小法廷:変造テレホンカード事件上告審判決 (最三決3. 4. 5) . 判例時報 1383:118-121, 1991.

• 76) 新美育文:承諾なき乳腺摘出手術. 別冊ジュリスト No50 医事判例百選. 有斐閣, pp.82-83, 1976.

• 77) 富田功一:医療事故. 上山滋太郎, 富田功一編, 標準法医学・医事法制. 医学書院, pp.270-288, 1984.

• 78) 大谷実:医療行為と法. 弘文堂, pp.49-57, 1980.

• 79) 唄 孝一, 宇都木伸, 平林勝政:別冊ジュリスト No102 医療過誤判例百選. 有斐閣, 1989.

• 80) 饗庭忠男:医療事故の焦点. 日本医事新報社, 1987.

• 81) 平林勝政:一時外泊中の脳出血死事件. 別冊ジュリスト No102 医療過誤判例百選. 有斐閣, pp.204-206, 1989.

• 82) 中川 淳, 大野真義編:医療関係者法学. 世界思想社, pp.59-76, 1989.

• 83) 竜嵜喜助:診療録閲覧請求事件. 別冊ジュリスト No102 医療過誤判例百選. 有斐閣, pp.226-227, 1989.

• 84) Weinstein MC:Allocation of subjects in medical experiments. N. Engl. J. Med. 291:1278-1285, 1974.
  pubmed

• 85) Burkhardt R, Kienle G:Controlled clinical trials and medical ethics. Lancet ii:1356-1259, 1978.

• 86) Angell M:Patients'preferences in randomized clinical trials. N. Engl. J. Med. 310:1385-1387, 1984.
  pubmed

• 87) Hellman S, Hellman DS:Of mice but not men:problems of the randomized clinical trial. N. Engl. J. Med. 324:1585-1589, 1991.

• 88) Pocock SJ:When to stop a clinical trial. Br. Med. J. 305:235-240, 1992.

• 89) Schafer A:The ethics of the randomized clinical trial. N Engl. J. Med. 307:719-724, 1982.
  pubmed

• 90) Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, Gruttola VD, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S, Lefkopoulou M, Tsiatis A, Zelen M, Peto J, Freedman LS, Gail M, Simon R, Ellenberg SS, Anderson JR, Collins R, Peto R, Peto T:Design considerations for AIDS trials. N. Engl. J. Med. 323:1343-1348, 1990.

• 91) Freedman B:Equipoise and the ethics of clinical research. N. Engl. J. Med. 317:141-145, 1987.
  pubmed

• 92) Altman DG:Statistics and ethics in medical research-Misuse of statistics is unethical. Br. Med. J. 281 :1182-1184, 1980.
  pubmed

• 93) Beecher HK:Surgery as a placebo:A quantitative study of bias. JAMA 176:1102-1107, 1961.
  pubmed

• 94) Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA:An evaluation of internalmammary artery litigation by a double blind technic. N. Engl. J. Med. 260:1115-1118, 1959.

• 95) Dimond EG, Kittle CF, Crockett JE:Evaluation of internal and sham procedure in angina pectoris. Circulation 18:712-713, 1958.

• 96) 砂原茂一訳:ヘルシンキ宣言. 臨床薬理 6:375-378, 1975.

• 97) 加藤一郎:臨床試験と人権. 加藤一郎, 森島昭夫編集, 医療と人権. 有斐閣, pp.309-330, 1984.

• 98) 光石忠敬:共同作業への証としてのインフォームド・コンセント-臨床試験と人権について考える-. 臨床評価 16:569-580, 1988.

• 99) Kerrigan DD, Thevasagayam RS, Woods TO, McWelch I, Thomas WEG, Shorthouse AJ, Dennison AR:Who's afraid of informed consent? Br. Med. J. 306:298-300, 1993.

• 100) Simes RJ, Tattersall MHN, Coates AS, Raghavan D, Solomon HJ, Smartt H:Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br. Med. J. 293:1065-1068, 1986.

• 101) Lachin JM:Introduction to sample size determination and power analysis for clinical trials. Controlled Clin. Trials 2:93-113, 1981.
  pubmed

• 102) Donner A:Approaches to sample size estimation in the design of clinical trials-A review. Stat. Med. 3:199-214, 1984.
  pubmed

• 103) Dupont WD, Plummer WD Jr:Power and sample size calculations-A review and computer program. Controlled Clin. Trials 11:116-128, 1990.
  pubmed

• 104) 佐久間昭:医学統計Q&A. 日本消化器学会編, 金原出版. pp.17-22, 1987.

• 105) 富永祐民:治療効果判定のための実用統計学-生命表法の解説と臨床試験の実際-第3回改訂版. 蟹書房. 1991.

• 106) Gardner M, et al eds:Statistics with Confidence-Confidence Intervals and Statistical Guideline. British Medical Journal, London, 1989.

• 107) 浜島信之:生物統計学と臨床研究の狭間における諸問題. 癌生時研誌 12:11-17, 1992.

• 108) 浜島信之:多変量解析による臨床研究 第2版. 比例ハザードモデルとロジスティックモデルの解説とSASプログラム, 名古屋大学出版会, 1993.

• 109) Blackwelder WC, Chang MA:Sample size graphs for "proving the null hypothesis". Controlled Clin. Trials 5:97-105, 1984.
  pubmed

• 110) Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW:A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococal meningitis. N. Engl. J. Med. 301:126-131, 1979.

• 111) 辻 克和, 岡村菊夫, 三宅弘治, 吉田和彦, 村瀬達良, 小谷俊一, 瀧田 徹, 絹川常郎, 伊藤浩一, 榊原敏文, 伊藤 博, 金井 茂, 浜島信之:(印刷中) 経尿道的前立腺切除術における予防的抗生剤投与法の検討-経口剤投与と注射剤投与法の比較-. 泌尿器科紀要.

• 112) Schoenfeld DA, Richter JR:Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38:163-170, 1982.
  pubmed

• 113) Gail MH:Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. Controlled Clin. Trials 6:112-119, 1985.
  pubmed

• 114) Cox DR:Regression models and life-tables. J. Royal Stat. Soc. Series B. 34:187-220, 1972.

• 115) Cuzick J:The efficiency of the proportions test and the logrank test for censored survival data. Biometrics 38:1033-1039, 1982.

• 116) Willan AR:Relative efficiency in survival analysis. J. Chron. Dis. 36:183-192, 1983.
  pubmed

• 117) Freedman LS:Tables of the number of patients required in clinical trials using the logrank test. Stat. Med. 1 :121-129, 1982.
  pubmed

• 118) 浜島信之:臨床試験での必要症例数. 日癌治 27:847-856, 1992.

• 119) Kleinbaum DG, Kupper LL, Morgenstern H:Epidemiologic Research-Principles and Quantitative Methods. Van Nostrand Reinhold Company, New York, 1982.

• 120) Shea S, Bigger JTJr, Campion J, Fleiss JL, Rolnitzky LM, Schron E, Gorkin L, Handshaw K, Kinney MR, Branyon M:Enrollment in clinical trials:Institutional factors affecting enrollment in the Cardiac Arrhythmia Suppression Trial (CAST) . Cotrolled Clin. Trtals 13:466-486, 1992.

• 121) Yusuf S, Held P, Teo KK, Toretsky ER:Selection of patients for randomized controlled trials:implications of wide or narrow eligibility criteria. Stat. Med. 9:73-86, 1990.
  pubmed

• 122) Efron B:Forcing a sequential experiment to be balanced. Biometrika 58:403-417, 1971.

• 123) Blackwell D, Hodges JLJr:Design for the control of selection bias. Ann. Math. Stat. 28:449-460, 1957.

• 124) Stigler SM:The use of random allocation for the control of selection bias. Biometrika 56:553-560, 1969.

• 125) Zelen M:Play the winner rule and the controlled clinical trial. JASA 64:131-146, 1969.

• 126) Zelen M:The randomization and stratification of patients to clinical trials. J. Chron. Dis. 27:365-375, 1974.
  pubmed

• 127) Grizzle JE:Anote on stratifying versus complete random assignment in clinical trials. Controlled Clin. Trials 3:365-368, 1982.

• 128) Brown BWJr:Designing for cancer clinical trials:Selection of prognostic factors. Cancer Treat. Rep. 64:499-502, 1980.
  pubmed

• 129) Meier P:Stratification in the design of a clinical trial. Controlled Clin. Trials 1:335-361, 1981.

• 130) Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG:Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br. J. Cancer 34:585-612, 1976.
  pubmed

• 131) Pocock SJ:Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975.
  pubmed

• 132) White SJ, Freedman LS:Allocation of patients to treatment groups in a controlled clinical study. Br. J. Cancer 37:849-857, 1978.

• 133) 坂本純一, 中里博昭, 大橋靖雄, 田村 弘, 宮崎照子, 市橋秀仁:臨床試験における最小化法 (minimization method) の適用. 癌生時研誌 8:59-63, 1988.

• 134) Sylvester RJ, Pinedo HM, DePauw M, Staquet MJ, Buyse ME, Renard J, Bonadonna G, the Active Participants in the EORTC Soft Tissue and Bone Sarcoma Cooperative Group:Quality of institutional participation in multicenter clinical trials. N. Engl. J. Med. 305:852-855, 1981.

• 135) The Multicenter Postinfarction Research Group:Risk stratification and survival after myocardial infarction. N. Engl. J. Med. 309:331-336, 1983.

• 136) Kalish LA, Begg CB:Treatment allocation methods in clinical trials:a review. Stat. Med. 4:129-144, 1985.
  pubmed

• 137) Simon R:Restricted randomization designs in clinical trials. Biometrics 35:503-512, 1979.
  pubmed

• 138) Brown BW:Statistical controversies in the design of clinical trials-some personal views. Controlled Clin. Trials 1:13-27, 1980.

• 139) 大橋靖雄:癌の臨床試験におけるランダム化. 癌生時研誌 8:99-111, 1988.

• 140) Klotz JH:Maximum entropy constrained balance randomization for clinical trials. Biometrics 34:283-287, 1978.
  pubmed

• 141) Nordle O, Brantmark B:A self-adjusting randomization plan for allocation of patients into two treatment groups. Clin. Pharmacol. Ther. 22:825-830, 1977.
  pubmed

• 142) Begg CB, Iglewicz B:Atreatment allocation procedure for sequential clinical trials. Biometrics 36:81-90, 1980.

• 143) Atkinson AC:Optimum biased coin designs for sequential clinical trials with prognostic factors. Biometrika 69:61-67, 1982.

• 144) 團野 誠, 坂本純一, 中里博昭:多施設共同研究におけるコンピュータネットワーク登録割付システム. 癌生時研誌 12:75-82, 1992.

• 145) Jones DR:The future of statistics and statisticians in European regulatory affairs. Controlled Clin. Trials 13:459-465, 1992.
  pubmed

• 146) Wright P, Haybittle J:Design of forms for clinical trials (1) . Br. Med. J. 2:529-530, 1979.
  pubmed

• 147) Gore SM:Assessing clinical trials-record sheets. Bz. Med. J. 283:296-298, 1981.

• 148) Steward WP, Vantongelen K, Verweij J, Thomas D, Van Oosterom AT:Chemotherapy administration and data collection in an EORTC Collaborative Group-Can we trust the results? Eur. J. Cancer 29A:943-947, 1993.

• 149) Reynolds-Haertle RA, McBride R:Single vs. double data entry in CAST. Controlled Clin. Trials 13:487-494, 1992.
  pubmed

• 150) The Steering Committee of the Physicians'Health Study Research Group:Preliminary report:findings from the aspirin component of the ongoing physicians'health study. N. Eng. J. Med. 318:262-264, 1988.

• 151) Steering Committee of the Physicians'Health Study Research Group:Final report on the aspirin component of the ongoing physicians'health study. N. Engl. J. Med. 321:129-135, 1989.

• 152) Flemming TR, 大野竜三:臨床試験のデザイン法. 癌と化学療法 15:568-573, 1988.

• 153) Armitage P, McPherson K, Rowe BC:Repeated significance tests on accumulating data. J. Royal Stat. Soc. Series A:132:235-244, 1969.

• 154) Pocock SJ:Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977.

• 155) O'Brien PC, Flemming TR:Amultiple testing procedure for clinical trials. Biometrics 35:549-556, 1979.

• 156) Flemming TR, Harrington DP, O'Brien PC:Design for group sequential tests. Controlled Clin. Trials 5:348-361, 1984.

• 157) DeMets DL :Practical aspects in data monitoring:Abrief review. Stat. Med. 6:753-760, 1987.

• 158) Geller NL:Planned interim analysis and its role in cancer clinical trials. J. Clin. Oncol. 5:1485-1490, 1987.
  pubmed

• 159) Geller NL, Pocock SJ:Interim analyses in randomized clinical trials:Ramifications and guidelines for practitioners. Biometrics 43:213-223, 1987.
  pubmed

• 160) Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EFIII, Green MR:A randomized trial of induction chemotherapy plus high-dose radiationversus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med. 323:940-945, 1990.

• 161) Stiell IG, Hebert PC, Weitzman BN, Wells GA, Raman S, Stark RM, Higginson LAJ, Ahuja J, Dickinson GE:High-dose epinephrine in adult cardiac arrest. N. Engl. J. Med. 327:1045-1050, 1992.

• 162) The West of Scotland Coronary Prevention Study Group:A coronary primary prevention study of Scottish men aged 45-64 years:trial design. J. Clin. Epidemiol 45:849-860, 1992.

• 163) Errington RD, Ashby D, Gore SM, Abrams KR, Myint S, Bonnett DE, Blake SW, Saxton TE:High energy neutron treatment for pelvic cancers:study stopped because of increased mortality. Br. Med. J. 302:1045-1051, 1991.

• 164) Prevention of Atherosclerotic Complications with Ketanserin Trial Group:Prevention of atherosclerotic complications:controlled trial of ketanserin. Br. Med. J. 298:424-430, 1989.

• 165) Lan KK, Simon R, Halperin M:Stochastically curtailed sampling in long-term clinical trials. Communications in Statistics-Theory and Methods 13:2339-2353, 1984.

• 166) Henderson WG, Fisher SG, Weber L, Hammermeister KE, Sethi G:Conditional power for arbitary survival curves to decide whether to extend a clinical trial. Controlled Clin. Trials 12:304-313, 1991.

• 167) Ware JH, Muller JE, Braunwald E:The futility index:an approach to the cost-effective termination of randomized clinical trials. Am. J. Med. 78:635-643, 1985.

• 168) Armitage P:Sequential Medical Trials, 2nd Edition. Blackwell, Oxford, 1975.

• 169) Acute Leukemia Group:The effect of 6-MP on the duration of steroid-induced remissions in acute leukemia:A model for evaluation of other potentially useful therapy. Blood 62:699-716, 1963.

• 170) 浜島信之, 大野竜三:無作為比較対照試験における問題症例の統計解析上の取扱い. 日癌治 25:1537-1542, 1990.

• 171) Simon R, Wittes RE:Methodological guidelines for reports of clinical trials. Cancer Treat. Rep. 69:1-3, 1985.
  pubmed

• 172) Bhaskar R, Reitman D, Sacks HS, Smith H Jr, Chalmers TC:Loss of patients in clinical trials that measure long-term survival following myocardial infarction. Controlled Clin. Trials 7:134-148, 1986.
  pubmed

• 173) 浜島信之, 大野竜三:Randomization後の治療法変更の影響. 癌生時研誌 9:32-36, 1989.

• 174) Cupples LA, Heeren T, Schatzkin A, Colton T:Multiple testing of hypotheses in comparing two groups. Ann. Intern. Med. 100:122-129, 1984.
  pubmed

• 175) Mantel N, Haenszel W:Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 22:719-748, 1959.
  pubmed

• 176) Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG:Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br. J. Cancer 35:1-39, 1977.
  pubmed

• 177) Breslow NE, Day NE:Statistical Methods in Cancer Research Volume I-the Analysis of Case-control Studies, IARC Scientific Publications, No. 33, Lyon, 1980.

• 178) Bailar JC III, Mosteller F:Guidelines for statistical reporting in articles for medical journals- Amplifications and explanations. Ann. Intern Med. 108:266-273, 1988.

• 179) Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC:Meta-analyses of randomized controlled trials. N. Engl. J. Med. 316:450-455, 1987.
  pubmed

• 180) Felson DT:Bias in meta-analytic research. J. Clin. Epidemiol. 45:885-892, 1992.

• 181) Chalmers TC:The impact of controlled trials on practice of rnedicine. Mt. Sinai J. Med. 41 :753-759, 1974.
  pubmed

• 182) Fineberg HV:Clinical evaluation:how does it influence medical practice? Bull. Cancer (Paris) 74:333-346, 1987.
  pubmed

• 183) Furberg CD:The impact of clinical trials on clinical practice. A rzneimittelforschung 39:986-988, 1989.
  pubmed

• 184) Lamas GL, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J, Braunwald E, for the SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N. Engl. J. Med. 327:241-247. 1992.

• 185) Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R:Randomized trial of prophylactic daily aspirinin British male doctors. Br. Med. J. 296:313-316, 1988.

• 186) Second International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardiac infarction:ISIS-2. Lancet ii:349-360, 1988.

• 187) The Israeli Sprint Study Group:Secondary prevention reinfarction Israeli nifedipine trial:(SPRINT) :a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur. Heart J. 9:354-364, 1988.

• 188) The Multicenter Diltiazem Postinfarction Trial Research Group:The effect of diltiazem on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 319:385-392, 1988.

• 189) Merigan TC:You can teach an old dog new tricks:how AIDS trials are pioneering new strategies. N. Engl. J. Med. 323:1341-1343, 1990.
  pubmed

• 190) Mariner WK:New FDA drug approval policies and HIV vaccine development. Am. J. Public Health 80:336-341, 1990.
  pubmed

• 191) 須磨忠昭:米JCAHにみる病院機能評価. Nikkei Medical 1988年2月10日号 pp.193-200, 1988.